Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics
France-based Pierre Fabre Laboratories announced the acquisition of global rights to PFL-721 and PFL-241 from...
Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers
China-based Hasten Biopharmaceutical Co., Ltd, backed by CBC Group, announced the completion of Market Authorization...
Sino Biopharmaceutical’s TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Class 1 drug TDI01 has been...
3D Medicines Partners with MGI Tech for Precision Medicine Solutions in Oncology and Infectious Diseases
China-based 3D Medicines (HKG: 1244) announced a strategic collaboration with domestic gene sequencing specialist MGI...
Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia
China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical...
BioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline
France-based BioMérieux is set to acquire the assets of Day Zero Diagnostics, a US-based infectious...
Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy
China-based Suzhou GenAssist Therapeutic Co., Ltd. announced that its in vivo base editing therapy, GEN6050X,...
BioTroy Therapeutics Secures USD 28M in Series A Funding for CD3L1 Anti-Tumor Drug Development
Shanghai-based BioTroy Therapeutics, a cancer immunotherapy developer, has reportedly secured over RMB 200 million (USD...
GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology
US-based GlycoT Therapeutics LLC last week inked a license agreement with Innovent Biologics, Inc. (HKG:...
Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC
China-based Shanghai Escugen has partnered with Spain-headquartered SunRock Biopharma, S.L. to co – develop SRB123,...
AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial
US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...
Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute
China-based Harbour BioMed (HKG: 2142) announced that the China National Intellectual Property Administration (CNIPA) has...
Roche Advances Prasinezumab to Phase III for Early Parkinson’s Disease
Switzerland-based Roche (SWX: ROG, OTCMKTS: RHHBY) announced its decision to advance prasinezumab, an anti-α-synuclein antibody...
Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming and US-headquartered NextCure, Inc. (NASDAQ:...
AstraZeneca’s Oncology Executive Michael Lai to Leave Company in June
Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and...
Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion
US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...
Pediatrix Therapeutics Wins Macau Approval for Neffy Epinephrine Nasal Spray
China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy...
Minova Pharmaceuticals Launches Rongzhi, China’s First Injectable Adipocytolytic Drug
Nanjing-based Minova Pharmaceuticals Co., Ltd announced last week that it has received marketing approval from...
RemeGen Secures 1,827-Day Patent Extension for Telitacicept in China
China-based pharmaceutical firm RemeGen (HKG: 9995) announced that the China National Intellectual Property Administration has...
Fujian Cosunter Gains Ethics Approval for Phase III Study of Neracorvir in CHB Patients
China-based Fujian Cosunter Pharmaceutical Co., Ltd. (SHE: 300436) announced that it has received ethical approval...